JP2008500366A5 - - Google Patents

Download PDF

Info

Publication number
JP2008500366A5
JP2008500366A5 JP2007515355A JP2007515355A JP2008500366A5 JP 2008500366 A5 JP2008500366 A5 JP 2008500366A5 JP 2007515355 A JP2007515355 A JP 2007515355A JP 2007515355 A JP2007515355 A JP 2007515355A JP 2008500366 A5 JP2008500366 A5 JP 2008500366A5
Authority
JP
Japan
Prior art keywords
moiety
aryl
heteroaryl
heterocyclic
alicyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007515355A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008500366A (ja
JP5149001B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/018603 external-priority patent/WO2006001967A2/en
Publication of JP2008500366A publication Critical patent/JP2008500366A/ja
Publication of JP2008500366A5 publication Critical patent/JP2008500366A5/ja
Application granted granted Critical
Publication of JP5149001B2 publication Critical patent/JP5149001B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007515355A 2004-05-25 2005-05-25 癌の処置におけるマイグラスタチンアナログ Expired - Fee Related JP5149001B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57411404P 2004-05-25 2004-05-25
US60/574,114 2004-05-25
PCT/US2005/018603 WO2006001967A2 (en) 2004-05-25 2005-05-25 Migrastatin analogs in the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008136097A Division JP2008273981A (ja) 2004-05-25 2008-05-23 癌の処置におけるマイグラスタチンアナログ

Publications (3)

Publication Number Publication Date
JP2008500366A JP2008500366A (ja) 2008-01-10
JP2008500366A5 true JP2008500366A5 (OSRAM) 2008-07-10
JP5149001B2 JP5149001B2 (ja) 2013-02-20

Family

ID=35355865

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007515355A Expired - Fee Related JP5149001B2 (ja) 2004-05-25 2005-05-25 癌の処置におけるマイグラスタチンアナログ
JP2008136097A Pending JP2008273981A (ja) 2004-05-25 2008-05-23 癌の処置におけるマイグラスタチンアナログ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008136097A Pending JP2008273981A (ja) 2004-05-25 2008-05-23 癌の処置におけるマイグラスタチンアナログ

Country Status (3)

Country Link
US (1) US8957056B2 (OSRAM)
JP (2) JP5149001B2 (OSRAM)
WO (1) WO2006001967A2 (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1608626A1 (en) 2003-03-28 2005-12-28 Cornell Research Foundation, Inc. Migrastatin analog compositions and uses thereof
JP5149001B2 (ja) 2004-05-25 2013-02-20 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ 癌の処置におけるマイグラスタチンアナログ
US8188141B2 (en) * 2004-09-23 2012-05-29 Sloan-Kettering Institute For Cancer Research Isomigrastatin analogs in the treatment of cancer
SI2109623T1 (sl) * 2006-05-22 2012-05-31 Xbiotech Inc Zdravljenje raka z anti il protitelesi
US20080312317A1 (en) * 2007-04-12 2008-12-18 Eisai R&D Management Co., Ltd. 12 membered-ring macrolactam derivatives
CA2707009A1 (en) * 2007-11-21 2009-06-04 Cornell University Methods for inhibiting fascin
PL2285409T3 (pl) 2008-05-30 2016-10-31 Przeciwciała il-1 alfa
EP2379074B1 (en) * 2008-12-17 2013-11-13 Sanofi Macrolactone derivatives, method for the production thereof and use thereof for the treatment of cancer
US9420770B2 (en) 2009-12-01 2016-08-23 Indiana University Research & Technology Corporation Methods of modulating thrombocytopenia and modified transgenic pigs
ES2703774T3 (es) 2010-06-18 2019-03-12 Xbiotech Inc Tratamiento para la artritis
NZ607472A (en) 2010-08-23 2014-09-26 Xbiotech Inc Treatment for neoplastic diseases
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
KR102004554B1 (ko) 2011-04-01 2019-10-01 엑스바이오테크, 인크. 피부과학적 병리의 치료
CN103635088B (zh) * 2011-04-07 2016-06-15 索隆-基特林癌症研究协会 米格拉他汀类(Migrastatins)和其用途
WO2013013240A2 (en) * 2011-07-21 2013-01-24 Theracrine, Inc. Macrocyclic compounds and related compositons and methods of use
MX356808B (es) 2011-09-23 2018-06-14 Xbiotech Inc Uso de una composición farmacéutica que comprende un anticuerpo anti-il-1a para el tratamiento de la caquexia.
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
JP6783224B2 (ja) 2014-04-04 2020-11-11 デル マー ファーマシューティカルズ 肺の非小細胞癌腫及び卵巣癌を処置するためのジアンヒドロガラクチトール及びその類縁体又は誘導体の使用
EP3582813A4 (en) 2017-02-16 2020-12-30 XBiotech, Inc TREATMENT OF SUPPURATIVE HIDRADENITIS
CA3095740A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin alpha (il-1a)
CA3095679A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleuken 1 alpha (il-1a)
CA3095675A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
CA3095676A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL66434C (OSRAM) 1946-12-06
FR1264032A (fr) 1960-05-06 1961-06-19 Rhone Poulenc Sa Acide cycloundecanecarboxylique
GB1036084A (en) 1962-02-23 1966-07-13 Upjohn Co Oxygenated cycloalkanes and the preparation thereof
NL302921A (OSRAM) 1963-01-21
DE2934678A1 (de) 1979-08-28 1981-03-12 Haarmann & Reimer Gmbh, 3450 Holzminden Cyclopentadecen-8-on-1, verfahren zu seiner herstellung und seine verwendung als riechstoff
DE2934683A1 (de) 1979-08-28 1981-03-12 Haarmann & Reimer Gmbh, 3450 Holzminden 3-methyl-cyclohexadecen-5-on-1, verfahren zu seiner herstellung und seine verwendung als riechstoff.
US4472435A (en) 1980-07-31 1984-09-18 Hoffman-La Roche Inc. Benzophenone derivatives useful in treating heart failure
JPS6156146A (ja) 1984-08-28 1986-03-20 Nippon Mining Co Ltd 大環状ケトンの製造方法
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
EP0374445A1 (fr) 1988-12-23 1990-06-27 Firmenich Sa Nouveaux composés cycliques oxygénés, leur utilisation à titre d'ingrédients parfumants, procédé pour leur préparation
JPH07138257A (ja) 1993-11-16 1995-05-30 Taisho Pharmaceut Co Ltd 骨吸収抑制物質ｂｒ−０４０及びｂｒ−０４２
ZA989885B (en) 1997-10-31 1999-05-05 Abbott Lab Use of macrolides for the treatment of cancer and macular degeneration
EP0976714A1 (en) 1998-07-06 2000-02-02 Quest International B.V. Addition of ketones to alkenes
SG80643A1 (en) 1998-09-03 2001-05-22 Givaudan Roure Int Methylcyclotetradec-5-en-1-ones
JP2000247949A (ja) 1999-02-26 2000-09-12 Eisai Co Ltd スルホンアミド含有インドール化合物
JP2001078793A (ja) 1999-09-10 2001-03-27 Nippon Kayaku Co Ltd 新規生理活性物質の醗酵法による製造法
JP2001081088A (ja) 1999-09-10 2001-03-27 Nippon Kayaku Co Ltd 新規生理活性物質ｎｋ３０４２４類縁体とそれらの製造法および用途
AU2401401A (en) 1999-12-22 2001-07-03 Zaidan Hojin Biseibutsu Kagaku Kenkyukai Migrastatin, process for producing the same and medicinal compositions
US6750047B2 (en) * 2000-08-21 2004-06-15 Kosan Biosciences, Inc. Fermentation and purification of migrastatin and analog
US6660306B2 (en) 2000-10-12 2003-12-09 Mickey L. Peshoff Wound healing compound
TWI312681B (en) 2001-02-01 2009-08-01 Novel physiologically active substance
DE60206151D1 (de) 2001-04-26 2005-10-20 Ecopia Biosciences Inc Gene und proteine für polyketide biosynthese
DE60216362T2 (de) 2001-06-08 2007-09-20 Takasago International Corp. Inhibitoren der Melaninherstellung und solche Inhibitoren enthaltende Hautpflegemittel
JP2003104967A (ja) * 2001-09-28 2003-04-09 Takuma Sasaki ウロキナーゼ産生阻害剤、血管新生阻害剤、癌転移抑制剤および抗腫瘍剤
JP3973889B2 (ja) 2001-12-04 2007-09-12 株式会社ジャパンエナジー 大環状ケトン化合物の製造方法
CN100391753C (zh) 2002-07-23 2008-06-04 米其林技术公司 具有非直线固定加强件的轮胎
WO2004052359A1 (en) 2002-12-09 2004-06-24 The Board Of Regents Of The University Of Texas System Methods for selectively inhibiting janus tyrosine kinase 3 (jak3)
WO2004083164A1 (ja) 2003-03-19 2004-09-30 Ube Industries, Ltd. ωーシアノアルデヒド化合物の製造法
US20070037783A1 (en) 2003-03-28 2007-02-15 Xin-Yun Huang Migrastatin analogs and uses thereof
EP1608626A1 (en) 2003-03-28 2005-12-28 Cornell Research Foundation, Inc. Migrastatin analog compositions and uses thereof
WO2005019181A1 (en) 2003-08-19 2005-03-03 Cornell Research Foundation, Inc. Migrastatin analog cell migration inhibitors
JP5149001B2 (ja) 2004-05-25 2013-02-20 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ 癌の処置におけるマイグラスタチンアナログ
US8188141B2 (en) 2004-09-23 2012-05-29 Sloan-Kettering Institute For Cancer Research Isomigrastatin analogs in the treatment of cancer
CA2707009A1 (en) 2007-11-21 2009-06-04 Cornell University Methods for inhibiting fascin

Similar Documents

Publication Publication Date Title
US20250120947A1 (en) Compounds and methods to sensitize cancer cells to cisplatin
ES2978534T3 (es) Análogos de éter de fosfolípidos como vehículos de fármacos contra el cáncer
AU2002210993B2 (en) Medicinal compositions for concominant use as anticancer agents
JP2008523099A5 (OSRAM)
WO2025083472A2 (en) Protac compounds binding keap1 ubiquitin ligase for targeted protein degradation
JP2008535902A5 (OSRAM)
ES2377975T3 (es) Composición medicinal que comprende un inhibidor de la HMG-CoA reductasa y un derivado de aminoalcohol como inmunodepresor
JP6002835B2 (ja) 低用量イリノテカン塩酸塩水和物を含有する抗腫瘍剤
RU2011142750A (ru) Способ лечения путем применения комбинированной терапии
JP2015500209A5 (OSRAM)
JP2012528858A5 (OSRAM)
JP2006523233A5 (OSRAM)
ES2746105T3 (es) Profármacos de 5-aza-pirimidina sililada útiles para tratar el cáncer
JP2006508965A5 (OSRAM)
JP2006510658A5 (OSRAM)
JP2013504590A5 (OSRAM)
CN109956986A (zh) 肝递送吉西他滨前体药物核苷环磷酸酯化合物及应用
ES2701123T3 (es) Derivados de taxano solubles en agua y sus usos
JP2006521407A5 (OSRAM)
JP2013525290A5 (OSRAM)
RU2004111787A (ru) Ретиноидные агонисты (1), производные алкилмочевины
WO2022214937A1 (en) Substituted tetracyclic carboxylic acids, analogues thereof, and methods using same
JP5701387B2 (ja) ベルバミンのジカルボキシミド誘導体、その調製方法及び使用
JP2003535890A5 (OSRAM)
SK18332002A3 (sk) Farmaceutický prostriedok obsahujúci farmaceuticky prijateľný nosič alebo masťový základ a ako aktívnu prísadu derivát akryloyldistamycínu a inhibítor topoizomerázy I a II